This time, the company plans to issue 22.19 million shares on North Exchange (without considering the over-allotment option ); the company and the lead underwriter choose to adopt the over-allotment option, and the number of shares issued with the over-allotment option accounts for 15% of the initial number of shares issued in this issue (i.e. 3.3285 million shares); if the over-allotment option is fully exercised, the number of shares issued this time will be 25.5185 million shares, with a total share capital of 88.78 million shares after issuance, and the issue price is 15.00 yuan per share.
1. Main business
Company is a high-tech enterprise specializing in providing scientific experimental instruments and equipment for users in the field of life science research and industrialization. The company's core business activities are carried out around three categories of products: biological sample processing, molecular biology and drug research, laboratory automation and general equipment. The issuer's products are widely used and can be expanded to many fields such as biomedical , medical and health care, IVD, biosafety , food safety, disease prevention and control, inspection and quarantine, environmental protection and new materials research.
2. Main financial data and financial indicators
Main financial data and financial indicators in the past three years:
Main operating data and year-on-year changes from January to June 2022:
The company's operating income from January to June 2022 was 86.0879 million yuan, an increase of 23.03% year-on-year, and the net profit attributable to the parent company shareholders was 17.7477 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 23.03%. The net profit attributable to the parent company shareholders was 17.7470 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 23.03%. The net profit attributable to the parent company shareholders was 17.7470 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 17.7470 million yuan, a year-on-year increase of 2022. 14.20%, the net profit attributable to the parent company owner after deducting non-recurring gains and losses was RMB 16.0753 million, an increase of 4.31% year-on-year. The above data has been reviewed by the accountant.
III. Investment projects for raised funds
IV. Price-to-earnings ratio of stock issuance
The corresponding price-to-earnings ratio of this issue price is 15.00 yuan per share is: 28.54 times (Earnings per share is calculated based on the net profit attributable to the parent company shareholders before deducting non-recurring gains and losses in the 2021 year, divided by the total share capital after the issuance when the over-allotment option is considered).
is calculated based on the average closing price (pre-requalification) of the 20 trading days before September 14, 2022 (T-4 days) and the latest diluted earnings per share of the 2021 (2021 net profit calculated after deducting non-recurring gains and losses). Comparable companies in the same industry that are similar to the issuer's main business have an average static price-to-earnings ratio of 42.96 , the details are as follows:
5. Subscription recommendations
Company provides high-tech enterprises with scientific experimental instruments and equipment for users in the field of life science research and industrialization. Although the company's stock issuance price-to-earnings ratio is lower than the price-to-earnings ratio of comparable listed companies, considering whether the stock is issued on the Beijing Stock Exchange or there is still a certain risk of breaking the issue. Investors can choose to subscribe according to their own situation.
(I do not apply for it)
5. Special statement
(1) In addition to the subscription suggestions, the above content comes from the company's prospectus and information that the company has published publicly.
(2) New shares are risky, so you must be cautious when applying. The above suggestions are for reference only and are not your final subscription decision. The profit and loss results are borne by yourself.
